NEW YORK (GenomeWeb News) – Qiagen said today that it has acquired UK-based companion diagnostics firm DxS in a deal that could be worth as much as $130 million.

Qiagen said that the acquisition provides it with a strong leadership position in the personalized healthcare arena.

Further supporting that claim, Qiagen also disclosed that it has more than 15 collaborations with pharmaceutical companies to develop and/or market companion diagnostic products, which it believes is the deepest such portfolio in the industry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.